Stocktoria
Cue Biopharma, Inc. CUE
Cue Biopharma, Inc. financials (annual)
Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $27.5M | $9.3M | $5.5M | $1.2M | $14.9M | $3.2M | $3.5M | $1.1M | — |
| R&D expense | $37.7M | $36.3M | $40.8M | $38.6M | $41.3M | $33.5M | $27.5M | $28.5M | $18.9M |
| Operating income | -$26.6M | -$41.5M | -$52.1M | -$53.2M | -$43.7M | -$45.0M | -$36.8M | -$38.7M | -$23.2M |
| Interest expense | $100,000 | $100,000 | $100,000 | $109,000 | — | — | — | — | — |
| Income tax | $500,000 | $0 | — | $0 | $495,000 | $206,250 | $412,500 | $825,000 | — |
| Net income | -$26.6M | -$40.7M | -$50.7M | -$53.0M | -$44.2M | -$44.8M | -$36.7M | -$39.0M | -$23.2M |
| EPS (diluted) | $-0.28 | $-0.72 | $-1.11 | $-1.49 | $-1.41 | — | — | — | — |
| Operating cash flow | -$21.7M | -$36.3M | -$40.0M | -$41.8M | -$38.8M | -$32.5M | -$30.8M | -$26.4M | -$12.1M |
| Free cash flow | -$21.9M | -$36.4M | -$40.0M | -$42.0M | -$39.8M | -$33.1M | -$30.8M | -$28.3M | -$13.2M |
| Cash & equivalents | $27.1M | $22.5M | $48.5M | $51.6M | $64.4M | $74.9M | $44.3M | $20.8M | $63.5M |
| Total assets | $42.2M | $32.2M | $61.5M | $91.3M | $83.4M | $99.5M | $71.6M | $45.4M | $67.0M |
| Total liabilities | $15.8M | $14.7M | $24.4M | $25.6M | $17.9M | $20.6M | $17.0M | $11.4M | $5.3M |
| Shareholders' equity | $26.4M | $17.5M | $37.1M | $65.7M | $65.5M | $78.9M | $54.6M | $34.0M | $61.6M |
Growth · year-over-year · Revenue CAGR 57.5%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +195.7% | +69.2% | +341.0% | -91.7% | +373.7% | -8.8% | +202.7% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.